Butorphanol

Overview

Butorphanol (Stadol®, Torbutrol®, Torbugesic®) is a synthetic opioid agonist–antagonist commonly used in dogs and cats as a sedative, mild analgesic, and antitussive. It acts primarily as a kappa-opioid receptor agonist with antagonist activity at mu receptors.

In small animal practice, butorphanol is used more frequently for sedation than for analgesia because its analgesic effects are mild and of short duration (approximately 50 minutes in dogs and 90 minutes in cats). It is often combined with other sedatives, particularly alpha-2 agonists, to enhance both sedation and analgesic effects.

Mechanism of Action (MOA): Butorphanol produces analgesia primarily through kappa-receptor stimulation in the central nervous system and antagonizes mu-opioid receptors. This mu-antagonist activity allows it to partially reverse the respiratory and sedative effects of pure mu-agonists (e.g., morphine, hydromorphone) without completely eliminating analgesia. It also possesses significant antitussive activity and elevates the respiratory center threshold to carbon dioxide without markedly depressing respiratory sensitivity.

Indications

Butorphanol is used in dogs and cats as an antitussive, mild analgesic, and preanesthetic sedative. Because its analgesic effects are short in duration and limited to mild to moderate pain, it is more commonly selected for sedation or cough suppression than for primary pain management.

• Antitussive (dogs): FDA-approved for the relief of chronic, nonproductive cough associated with inflammatory conditions of the upper respiratory tract, including tracheobronchitis, tracheitis, laryngitis, pharyngitis, and tonsillitis.
• Mild to moderate pain (dogs and cats): Used for short-term control of pain associated with minor trauma or surgical procedures. Due to its short duration of action, repeat dosing or multimodal analgesia is often required.
• Preanesthetic medication: Commonly administered as part of a balanced anesthetic protocol to provide sedation and reduce anesthetic requirements, particularly when combined with alpha-2 agonists or other sedatives.
• Reversal of mu-opioid effects: May be used to partially reverse respiratory and CNS depression caused by pure mu-opioid agonists while maintaining some degree of analgesia.
• Adjunct in multimodal protocols: Frequently combined with alpha-2 agonists in dogs and cats to enhance sedation and improve overall perioperative management.

Dosage (Reference)

Dog

In dogs, butorphanol is primarily used for antitussive therapy or short-term mild analgesia. Because analgesic duration is short, repeat dosing or multimodal analgesia is often required.

Cat

In cats, butorphanol is labeled for relief of pain associated with trauma or surgical procedures. Analgesia is mild and of relatively short duration.

Warnings & Precautions

Butorphanol is a reversible opioid agonist–antagonist with a relatively wide safety margin; however, careful patient selection and dose adjustment are required in compromised animals or when used with other sedatives.

• Hepatic and renal disease: Use cautiously in patients with liver disease or severe hepatic dysfunction, as metabolism occurs primarily in the liver. Use caution in animals with significant renal impairment.
• Endocrine disorders: Use with caution in patients with hypothyroidism or adrenocortical insufficiency (Addison’s disease).
• Respiratory disease: Although respiratory depression is generally less severe than with pure mu-agonists, use cautiously in patients with obstructive respiratory disease. Because of cough suppression, avoid use in lower respiratory tract disease associated with excessive mucus production.
• Head trauma / CNS dysfunction: Use cautiously in animals with head trauma, increased intracranial pressure, or other central nervous system disorders (e.g., coma).
• Geriatric or debilitated patients: Increased sensitivity may occur; use lower initial doses and monitor closely.
• MDR1 (ABCB1) mutation in dogs: Dogs with the MDR1 mutation may experience more pronounced and prolonged sedation. Dose reduction (approximately 25% in heterozygotes and 30–50% in homozygotes) is recommended.
• Cardiovascular effects: Mild decreases in heart rate and arterial blood pressure may occur. Monitor heart rate, especially when combined with other sedatives.
• Concurrent sedatives or analgesics: Additive CNS and respiratory depression may occur when combined with other sedatives, anesthetics, or opioids.
• Heartworm disease (dogs): Safety has not been established; use cautiously.
• Product concentration differences: Injectable butorphanol is available in multiple concentrations (0.5 mg/mL, 2 mg/mL, 10 mg/mL). Doses should always be prescribed in mg/kg, not mL, to avoid overdose.
• Controlled substance: Classified as a Schedule IV (C-IV) controlled drug; secure storage and accurate record-keeping are required.

Drug Interactions

Most clinically significant interactions with butorphanol involve additive CNS depression, cardiovascular effects, or pharmacologic antagonism of other opioids. Careful dose adjustment and monitoring are recommended when combining with the following agents.

• Alpha-2 agonists (e.g., dexmedetomidine, xylazine): Increased risk of bradycardia and enhanced sedation when used concurrently.
• CNS depressants (e.g., anesthetic agents, benzodiazepines, barbiturates, antihistamines, phenothiazines, muscle relaxants, other opioids): Additive CNS and respiratory depression; dosage reduction and close monitoring recommended.
• Other opioids (e.g., morphine, hydromorphone, fentanyl): May antagonize some analgesic effects of pure mu-agonists and partially reverse their sedative or respiratory depressant effects. Withdrawal signs may occur in patients receiving chronic opioid therapy.
• Hydromorphone (cats): Administration of butorphanol after hydromorphone may shorten the duration of hydromorphone-induced antinociception.
• Inhalant anesthetics (e.g., isoflurane, sevoflurane): Opioids may reduce MAC requirements; anesthetic dose adjustments may be needed.
• ACE inhibitors (e.g., benazepril, enalapril), beta-blockers, calcium-channel blockers, diuretics: Increased risk of hypotension and orthostatic effects.
• Anticholinergics (e.g., atropine, glycopyrrolate): May increase risk of urinary retention, constipation, ileus, and additive CNS effects.
• Antidiarrheals: Increased risk of severe constipation and ileus.
• CYP3A inhibitors (e.g., cimetidine, erythromycin, itraconazole): May decrease hepatic metabolism of butorphanol, increasing risk of respiratory depression or prolonged sedation.
• Monoamine oxidase inhibitors (e.g., selegiline): Potential for enhanced CNS depression and hypotension; caution advised.
• Metoclopramide: Prokinetic effects may be reduced; additive CNS depression possible.
• Desmopressin: May increase risk of hyponatremia and water intoxication due to enhanced pharmacologic effects.
• Iohexol (intrathecal): Increased seizure risk; withhold butorphanol 48 hours before and 24 hours after intrathecal administration when possible.
• Cannabidiol: May enhance CNS depressant effects of opioids.

Side Effects & Overdose

Side Effects

Adverse effects of butorphanol in dogs and cats are generally dose-dependent and typically less severe than those seen with pure mu-opioid agonists. Most effects involve sedation, mild cardiovascular changes, or gastrointestinal alterations.

• Sedation: Most common effect; may range from mild drowsiness to marked tranquilization.
• Ataxia: Transient incoordination may occur, particularly after parenteral administration.
• Respiratory depression: Usually mild but possible, especially when combined with other sedatives.
• Excitement or dysphoria: May occur in some animals; paradoxical CNS stimulation is possible.
• Mydriasis and disorientation: Occasionally reported in dogs and cats.
• Hypersalivation: Increased salivation may be observed.
• Gastrointestinal effects: Anorexia, vomiting, or diarrhea are uncommon but possible. Decreased GI motility may occur.
• Bradycardia: Mild decreases in heart rate may occur and can be treated with anticholinergics if clinically significant.
• Reduced tear production: Especially when combined with alpha-2 agonists; ocular lubrication may be required.
• Mucus retention: Antitussive effect may lead to accumulation of respiratory secretions.

Overdose

Life-threatening overdoses are uncommon due to the wide safety margin; however, dosing errors may occur because multiple injectable concentrations are available. Clinical signs are typically related to CNS and cardiovascular depression.

• Marked CNS depression: Profound sedation, stupor, or collapse.
• Respiratory depression: Decreased respiratory rate and depth; severe cases may require ventilatory support.
• Bradycardia and hypotension: Cardiovascular monitoring is essential.
• Management: Administer IV naloxone to reverse opioid effects if clinically indicated.
• Supportive care: Provide oxygen supplementation, IV fluids, and vasopressors as needed. Mechanical ventilation may be required in severe cases.
• Seizure control: Diazepam may be administered if seizures occur.

Key Notes

Practical clinical considerations to optimize safe and effective use of butorphanol in dogs and cats:

• Short analgesic window: Best suited for brief procedures or short-term perioperative support; reassess pain frequently and transition to longer-acting analgesics when needed.
• Ceiling effect: Increasing the dose above recommended ranges does not proportionally increase analgesia due to partial agonist activity.
• Synergistic protocols: Frequently paired with alpha-2 agonists in small animal practice to improve overall sedation quality and procedural compliance.
• Antitussive strength: Provides significantly greater antitussive activity than codeine or dextromethorphan in dogs.
• Limited histamine release: Unlike morphine, does not typically cause clinically significant histamine-mediated vasodilation in dogs.
• Physical dependence risk: The likelihood of physical dependence is considered low in veterinary patients.
• Onset characteristics: After IV administration, onset is rapid, making it useful for short diagnostic or minor procedural interventions.
• Withdrawal consideration: May precipitate withdrawal signs in patients receiving chronic pure mu-opioid therapy due to its antagonist activity.